tetano
Editor, Senior Moderator
J Med Virol
. 2021 Apr 29.
doi: 10.1002/jmv.27049. Online ahead of print.
Treatment Patterns in US Patients Hospitalized With COVID-19 and Pulmonary Involvement
Jennie H Best[SUP] 1 [/SUP], Amanda M Kong[SUP] 2 [/SUP], Emma Kaplan-Lewis[SUP] 3 [/SUP], Otis W Brawley[SUP] 4 [/SUP], Rachel Baden[SUP] 5 [/SUP], James L Zazzali[SUP] 1 [/SUP], Karen S Miller[SUP] 6 [/SUP], James Loveless[SUP] 6 [/SUP], Krutika Jariwala-Parikh[SUP] 2 [/SUP], Shalini V Mohan[SUP] 1 [/SUP]
Affiliations
Abstract
This study describes the baseline characteristics and treatment patterns of US patients hospitalized with a diagnosis of coronavirus disease 2019 (COVID-19) and pulmonary involvement. Patients hospitalized with pulmonary involvement due to COVID-19 (first hospitalization) were identified in the IBM Explorys? electronic health records database. Demographics, baseline clinical characteristics, and in-hospital medications were assessed. For evaluation of in-hospital medications, results were stratified by race, geographic region, age and month of admission. Of 6564 hospitalized patients with COVID-19-related pulmonary involvement, 50.4% were male, and mean (SD) age was 62.6 (16.4) years; 75.2% and 23.6% of patients were from the South and Midwest, respectively, and 50.2% of patients were African American. Compared with African American patients, a numerically higher proportion of White patients received dexamethasone (19.7% vs 31.8%, respectively), nonsteroidal anti-inflammatory drugs (NSAIDs; 27.1% vs 34.9%), bronchodilators (19.8% vs 29.5%), and remdesivir (9.3% vs 21.0%). Numerically higher proportions of White patients than African American patients received select medications in the South but not in the Midwest. Compared with patients in the South, a numerically higher proportion of patients in the Midwest received dexamethasone (20.1% vs 34.5%, respectively), NSAIDs (19.6% vs 55.7%), bronchodilators (15.9% vs 41.3%), and remdesivir (10.6% vs 23.1%). Inpatient use of hydroxychloroquine decreased over time, whereas use of dexamethasone and remdesivir increased over time. Among US patients predominantly from the South and Midwest hospitalized with COVID-19 and pulmonary involvement, differences were seen in medication use between different races, geographic regions, and months of hospitalization. This article is protected by copyright. All rights reserved.
. 2021 Apr 29.
doi: 10.1002/jmv.27049. Online ahead of print.
Treatment Patterns in US Patients Hospitalized With COVID-19 and Pulmonary Involvement
Jennie H Best[SUP] 1 [/SUP], Amanda M Kong[SUP] 2 [/SUP], Emma Kaplan-Lewis[SUP] 3 [/SUP], Otis W Brawley[SUP] 4 [/SUP], Rachel Baden[SUP] 5 [/SUP], James L Zazzali[SUP] 1 [/SUP], Karen S Miller[SUP] 6 [/SUP], James Loveless[SUP] 6 [/SUP], Krutika Jariwala-Parikh[SUP] 2 [/SUP], Shalini V Mohan[SUP] 1 [/SUP]
Affiliations
- PMID: 33913536
- DOI: 10.1002/jmv.27049
Abstract
This study describes the baseline characteristics and treatment patterns of US patients hospitalized with a diagnosis of coronavirus disease 2019 (COVID-19) and pulmonary involvement. Patients hospitalized with pulmonary involvement due to COVID-19 (first hospitalization) were identified in the IBM Explorys? electronic health records database. Demographics, baseline clinical characteristics, and in-hospital medications were assessed. For evaluation of in-hospital medications, results were stratified by race, geographic region, age and month of admission. Of 6564 hospitalized patients with COVID-19-related pulmonary involvement, 50.4% were male, and mean (SD) age was 62.6 (16.4) years; 75.2% and 23.6% of patients were from the South and Midwest, respectively, and 50.2% of patients were African American. Compared with African American patients, a numerically higher proportion of White patients received dexamethasone (19.7% vs 31.8%, respectively), nonsteroidal anti-inflammatory drugs (NSAIDs; 27.1% vs 34.9%), bronchodilators (19.8% vs 29.5%), and remdesivir (9.3% vs 21.0%). Numerically higher proportions of White patients than African American patients received select medications in the South but not in the Midwest. Compared with patients in the South, a numerically higher proportion of patients in the Midwest received dexamethasone (20.1% vs 34.5%, respectively), NSAIDs (19.6% vs 55.7%), bronchodilators (15.9% vs 41.3%), and remdesivir (10.6% vs 23.1%). Inpatient use of hydroxychloroquine decreased over time, whereas use of dexamethasone and remdesivir increased over time. Among US patients predominantly from the South and Midwest hospitalized with COVID-19 and pulmonary involvement, differences were seen in medication use between different races, geographic regions, and months of hospitalization. This article is protected by copyright. All rights reserved.